This is an immunoradiometric assay of intact human parathyrin, hPTH(1-84). One antibody, directed against the Nterminal part of the hormone, was produced in goats and conjugated covalently to cellulose particles. hPTH(1-84) and the N-terminal fragments were extracted from EDTA-treated plasma by these particles and thus concentrated. Another antibody, against synthetic hPTH(53-84), was raised in rabbits; this bound to the C-terminal part of the hormone. The final step was labeling the second free binding site of this antibody with 1251-labeledTyr52-hPTH(53-84) and measuring the bound radioactivity. This assay can detect intact PTH in concentrations as low as 0.6 pmol/L (1.2 x 1016 mol per tube). The assay did not cross react with hPTH(1-34), hPTH(1 -44), hPTH(28-48), hPTH(39-84), hPTH(44-68), or hPTH(53-84) in concentrations up to 6400 pmol/L. In 60 normal subjects, hPTH(1 -84) concentrations ranged from 1.9 to 6.8 pmol/L; in 32 patients with primary hyperparathyroidism, from 7.0 to 80 pmol/L. The hormone was not detected in four patients with hypoparathyroidism. fragments of the hormone (1). The total immunoreactivity in the circulation consists largely of mid-regional and C-terminal fragments. Therefore, routine radioimmunoassays for PTH usually determine the mid-regional (sequence 44-68) or the Cterminal part (sequence 53-84) of the hormone (2, 3). The concentrations measured by these assays are, however, heavily influenced by kidney function. Concentrations can be high simply because of diminished clearance of these biologically inactive fragments, thus complicating the differentiation of hypercalcemia (1, 3). One way to overcome this unreliability is to measure the intact hormone (hP'l'H 1-84), thus permitting a more direct evaluation of the secretory activity of the parathyroid glands. Intact PTH seems to contain most of the bioactivity detected in plasma (4), and it reliably indicates parathyroid function (5).
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Measuring intact PTH still presents many problems. Owing to the rapid uptake and cleavage of hPTH(1-84) by the liver, intact PTH is removed from circulation within minutes (1). As a consequence, the concentrations in plasma are very low and radioimmunoassays directed against the primary cleavage region of P'FH (residues 28-48) were usually not sensitive enough to detect intact PTH in all healthy persons (6) . To obtain the necessary assay sensitivity, Lindall et al. extract and concentrate N-terminal fragments and intact PTH from samples. The intact hormone was finally detected in a subsequent immunoassay of midregion fragments (5) .
Another way of improving assay sensitivity is to use the immunoradiometric assay (IRMA) technique first described by Miles and Hales in 1968 (7) . The usually low nonspecific radioactive uptake makes it possible to detect very small changes in the specific uptake of the label (8) . Other advantages include a decrease in the time required for reactants to reach equilibrium, owing to a surplus of antibodies. Measuring the bioactive sequence hPTH(1-34) in a homologous IRMA of the classical one-site type was first reported by Papapoulos et a!. in 1980 (9), but even this sophisticated assay detected PTH in only 32% of healthy persons. Recently, determination of intact PTH by use of a two-site assay was reported to have shown excellent performance data, with a lower detection limit than radioimmunoassay (10).
We have developed a new type of two-site assay for
hPTH(1-84).
We use two antisera, directed against the Nterminal and the C-terminal part of the hormone, to ensure the detection of only the intact (or essentially intact) hormone and to avoid any competition between these two antibodies (Figure 1) . The extraction of intact P'FH and Nterminal fragments in a first step allowed us to eliminate all other components of serum, including the midregional and C-terminal fragments of the hormone.
Immunoextraction and concentration further enhanced the sensitivity of this assay. In addition, we describe a method for labeling antibodies indirectly without previous purification.
Materials and Methods

Reagents
Most chemicals were from Merck AG, Darmstadt, F.R.G. We prepared 1 L of bu/ferA (pH 7.4) by combining 800 mL of 67 mmol/L Na2HPO4 solution, 200 mL of 67 mmolJL KH2PO4, 1 g of sodium azide, 400 mg of EDTA, and 1 g of human serum albumin (Behringwerke AG, Marburg, F.R.G.). To prepare 1 L of buffer B, we combined 900 mL of buffer A and 100 mL of hypoparathyroid serum previously determined to contain no detectable amounts of intact PTH.
Standards
We prepared 10 per application. The goats were bled 10 to 14 days after each booster. We incubated these antisera with four radioiodinated hPTH fragments, to determine the titer and specificity of each antiserum. Bound tracer was determined by precipitation with antiserum against goat IgG in a usual double-antibody assay system. The finally selected antiserum G774 was analyzed more precisely by simultaneous incubation with tracer and various concentrations of unlabeled fragments.
We obtained the antiserum (R82) against the C-terminal part of the hormone by immunizing rabbits with synthetic hPTH(53-84). 
Preparation of Anti-hPTH(1 -38)-Cellulose
Before being covalently linked to cellulose, the N-terminal antiserum G774 was fractionated. We followed a procedure described by Hebert et al. (12) and carried out repeated precipitations with solutions of ammonium sulfate (Merck AG). The precipitate was dialyzed against isotonic saline (NaC1, 0.85 g/L) and finally against barbital buffer (50 mmol/L, pH 8.0). Activated cellulose was prepared by combining 5 g of microcrystalline cellulose (Sigma GmbH) with 0.61 g of 1,1'-carbonyldiimidazole (Sigma GmbH) dissolved in 25 mL of acetone as described by Chapman et al. (13) .
We covalently linked IgG as follows: 2 g of dried activated cellulose were combined with 10 mL of IgG solution (protein concentration, 5 g/L) and incubated overnight at 20 #{176}C. The subsequent washing procedure was done as reported by Chapman et al. (13) . The coupled product was stored at 4#{176}C at a cellulose concentration of 8 g/L in buffer A. The suspension was stable for at least four months. It was mixed on a magnetic stirring device just before use.
Radioiodination Procedure
We radiolabeled 1 g of Nle818,Tyr3'-hVl'H(1-34), TyrhPTH(28-48), Tyr-hPTH(44-68), and Tyr52-hPTH(53-84) with 0.5 mCi of NaI (Amersham Buchier, Braunschweig, F.R.G.) as described previously ( monthly; its specific activity was approximately 600 CiJg. The tracer was further diluted to about 50000 Bq/mL in buffer A to which human serum albumin was added to give a total albumin concentration of of 10 g/L.
Assay Procedure
Pipet 200 L of hPTH(1-84) standard, control sera (see Table 1 
Results
Antibody Characteristics
displace the tracer Tyr27-hPTH(28-48) from the antibody, whereas hPTH(1-34) and hPTH(39-84) were ineffective. Hence
Assay Development
We optimized several variables. We chose 4#{176}C as our assay incubation condition for all steps, because under these conditions the standard curves were steeper and the count rates were higher than at room temperature.
Incubation for 24 h for the first phase of the assay, 14 h for the second, and 20 h for the third proved to be long enough for the reactants to reach equilibrium.
A further extension of these incubation times did not increase the bound radioactivity of the highest standard (64 pmol/L).
The C-terminal antiserum R82 and the 'I-labeled Tyr52-hPTH(53-84) were added in excess. For economic reasons, however, only 0.8 mg of anti-hPTH(1-38)-cellulose was used per tube, thus resulting in a lower calibration curve for high standards (Figure 2) .
We observed no "hook" effect: with concentrations of hPTH(1-84) up to 4000 pmolJL, bound activity was increasing steadily.
If the tube contents were not mixed during the first phase of incubation, bound activity fell by 30% for the whole range of standard concentrations. The volume of incubation mixture chosen proved to be a determining factor in carrying out the assay. Owing to the low concentrations of hPTH(1-84) it was necessary to shift the equilibrium of the reactions towards the products. Figure 3 shows the increase in bound activity when the same quantity of tracer is dissolved in 20 pL of buffer rather than in 100 pL.
Assay Characteristics
Detection limit. The nonspecific uptake of the label was lower than 0.5% of the total activity added and reached values between 100 and 150 counts/mm (B0). The lowest detectable concentration was defined as the point lying 3 SD above the B0, as measured and calculated based on 32 samples of the zero standard. The lower limit of detection was 0.6 pmol/L, which is equal to 1.2 x 1016 mol or 1.1 pg of hPTH (1-84) 
Interference with C-terminal fragments.
We tested what influence C-terminal fragments had on measuring hPTH(1-84). Intra-and interassay variations were estimated by repeatedly measuring three control sera from a healthy, a hyperparathyroid, and a hypoparathyroid person (Table 1) .
Medium for the Preparation of Standards
Initial experiments
with buffer A as a diluent for the standards showed fiat standard curves. Therefore we investigated degradation and adsorption of intact PT!! in several media.
Adsorption. We added identical quantities of synthetic hPTH(1-84) to several solutions (serum, buffer A, buffer B, isotonic saline). After gentle mixing the solutions were five times into new tubes during the incubation period in order to enhance adsorptive losses. To exclude any differences during assay performance the samples were diluted twofold in hypoparathyroid serum before assaying, except for the serum samples diluted with buffer A. The serum sample revealed a concentration of 14 pmol of hPTH(1-84) per liter, without being influenced by repeated transfer into new vials. The sample in buffer A contained 13 pmolJL. The value dropped by repeated transfer to 9.8 pmol/L, an effect that was even stronger in the protein-free solution. Addition of 100 mL of hypoparathyroid serum to 900 mL of buffer A, however, proved to be sufficient to obviate any adsorptive loss. That was why we chose this solution, referred to as buffer B, as the diluent for standards.
We observed no change in the PTH content of these standards when they were stored at 4#{176}C for two days, or alter three freeze-thaw cycles. To detect nonspecific adsorption of hPTH(1-84) onto the large surface of the cellulose particles, we carried out the assay with cellulose that had been covalently coated with another protein. No standard curve was obtained.
Samples
We examined the stability of intact PTH in 20 samples of EDTA-treated plasma, heparinized plasma, and serum from healthy and hyperparathyroid persons while the samples were stored at 4#{176}C for two days. We observed no decrease in the concentrations measured in the plasma samples, whereas one normal serum specimen showed a slight decrease and a renal-dialysis specimen a substantial decrease in the concentrations measured. Adding 2 mg of EDTA to 1 mL of the latter sample lessened the loss. The concentration of intact P'FH fell from 210 to 77 pmoli'L within two days. When EDTA was added, it fell from 210 to only 160 pmol/L. Considering these preliminary results, we prefer EDTAplasma for sampling, but serum should also be suitable when it is frozen immediately after its separation from cells.
The concentrations of intact P'l'H did not change in several samples stored at -30 #{176}C for three months.
Clinical Use
Normal range. Sixty ostensibly healthy blood donors were assayed. In all samples, intact PTH was detectable. The concentrations ( Figure 5 ) ranged from 1.9 to 6.8 pmolJL (mean 3.7 pmol/L, median 3.3 pmol/L). 
Discussion
Classical radioimmunoassay methods were usually not specific enough to detect only intact PTH and, at the same time, not sensitive enough to measure the rather low amounts of intact PT!! in healthy persons (6). Pre-assay extraction steps improved the sensitivity such that the detection limit was 2 pmol/L. The use of columns for hPTH . By using the twosite method (7, 8, 10) we obtained a lower limit of detection, 0.6 pmolJL, which is sensitive enough to detect intact PT!! in all healthy persons, thus allowing one to distinguish hypoparathyroid patients from normal persons. Although our antibodies did not have a particularly high affinity, we achieved this sensitivity by adding reagents in excess and by working with small incubation volumes of about 25 pL, except for the extraction step.
The use of two antibodies against two distinct sites of the peptide (sequences 1-38 and 53-68) prevented any steric inhibition of antibody binding and assured measurement of only intact PTH, thus resulting in increased specificity compared with one-site methods.
Because this method is an immunochemical one, the term "intact PTH" used in this article refers not only to intact hPTH(1-84) in a narrow sense but also to smaller peptides containing the regions 1-38 and 53-68. Detection is, however, restricted to intact PTH in a physiological sense, i.e., PTH prior to cleavage in the region 34-37, which is thought to be the first important step in PT!! metabolism (1). The mean concentration of PTH in plasma of normal individuals, as detected by cytochemical bioassay (4), is 11.3 ng/L (1.2 pmol/L), which is lower than concentrations detected by the two-site immunoradiometric assay. This may be caused by alterations of the intact peptide in circulation-e.g., removal of only a few amino acids from the N-terminal end-that alter its bioactivity but might not influence its detection in our assay. The concentrations of intact PTH in plasma correlate closely, however, with values for circulating PTH bioactivity (5).
The mean of the normal range (3.7 pmolJL) was similar to the value reported by Lindall et al. 1 to 5.8 pmol/L, supplier's product information) , which is similar to the normal range of our assay (1.9 to 6.8 pmol/L). Measurement of intact PTH in such assays might lead to more-standardized results when the detection of PT!! is restricted to the intact, or essentially intact, hormone. By contrast, assays directed against the midregional or C-terminal part of the hormone often give very different values, because the various forms of inactive degradation products as well as the intact hormone are detected to different degrees, depending on the antisera used (2, 3) .
To extract and concentrate intact PTH and N-terminal fragments, we used prior incubation of the samples with the anti-hPTH(1-38)-cellulose.
This step required more time than the simultaneous addition of all assay components (10). On the other hand, this step allowed us to decrease the volume used in the subsequent incubations. In particular, this step removed circulating substances that might have interfered nonspecifically during the subsequent assay procedure and ensured that all C-terminal and midregional fragments were eliminated. Because high concentrations of these fragments can accumulate in patients suffering from renal failure (1), it was important to exclude any interference with these fragments. We did not label the C-terminal antibody directly, because the C-terminal antiserum was of low titer, and the necessary purification would have caused heavy losses. To circumvent this problem we labeled the antibodies indirectly. Oxidative damage to the C-terminal antibody was thus avoided, and the antiserum was used economically. This method was initially intended for use in screening several different C-terminal antisera for their suitability for this assay, but it also proved to be satisfactory even for routine assay purposes. The tracer peptide Tyr 2-hPTH(53-84) is commercially available, can be radioiodinated by a simple and reliable method (3), and is stable for at least six weeks. Indirect labeling of antibodies might be applied to other peptide hormone assays if it is intended to set up a two-site system on the basis of an established radioimmunoassay procedure.
The slight nonlinearity of samples containing large amounts of PTH required a reassay of samples in 10-fold dilution.
This effect may be provoked by circulating Nterminal fragments, which decrease the number of binding sites of the cellulose particles when plasma PTH concentrations are high. We intend to overcome this insufficiency by purifying the N-terminal antiserum, using affinity chromatography. This method ought to achieve a higher density of antibodies on the cellulose particles. Estimation of intact PTH by two-site assays seems to represent substantial progress in PTH measurement, and it facilitates the diagnosis of parathyroid disorders.
This work was supported by Deutsche Forschungsgemeinschaft (Schrn 400/7-1).
